Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types

View Full Paper
Ask AI
Bookmark
Share

Authors

KKK.H. KimJTJose TinajeroKSKaramjeet S. Sandhu

Discussion

Loading...

Member takes

Overview

Single-center analysis shows lower chronic graft-versus-host disease incidence in 462 patients, indicating cyclophosphamide's effectiveness across donor types.

Key Points

  • Cyclophosphamide-based prophylaxis reduced moderate-to-severe chronic graft-versus-host disease incidence.
  • Two-year cumulative incidence stood at 46% for haplo donors and 40% for both mMUD and MUD.
  • Assessment of fibrotic manifestations revealed scleroderma in 3% of patients with chronic graft-versus-host disease.
  • Results emphasize the efficacy of PTCy in reducing fibrotic complications across diverse transplant settings.

Cite This Study

Kim et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc9dhttps://doi.org/10.1182/blood-2025-935
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide2026 · 5 citations
  2. 2Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis2025
  3. 3Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants2025
  4. 4Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  5. 5Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study2025